Clinical meaning
Bilirubin metabolism involves the production, transport, conjugation, excretion, and enterohepatic circulation of this heme degradation product. The NP must understand each step to localize the cause of jaundice.
Production: Approximately 80% of bilirubin comes from hemoglobin breakdown in senescent red blood cells phagocytized by reticuloendothelial macrophages (primarily in the spleen). Heme oxygenase cleaves the porphyrin ring of heme, producing biliverdin, carbon monoxide, and free iron. Biliverdin reductase then converts biliverdin to unconjugated bilirubin (UCB), which is lipophilic and neurotoxic.
Transport: UCB is virtually insoluble in water and is transported in plasma tightly bound to albumin. This albumin binding prevents tissue deposition. Conditions that reduce albumin binding (hypoalbuminemia, acidosis, competing drugs like sulfonamides, ceftriaxone, and salicylates) increase free UCB and the risk of kernicterus in neonates.
Hepatic uptake and conjugation: UCB is taken up by hepatocytes via organic anion transporting polypeptides (OATPs) on the sinusoidal membrane. Inside the hepatocyte, UCB is conjugated with glucuronic acid by uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) in the endoplasmic reticulum, producing water-soluble conjugated (direct) bilirubin. Gilbert syndrome results from a promoter polymorphism reducing UGT1A1 expression by 30% (benign, mild unconjugated hyperbilirubinemia exacerbated by fasting, stress, illness). Crigler-Najjar Type I is complete absence of UGT1A1 (severe unconjugated hyperbilirubinemia, kernicterus risk, requires phototherapy or liver transplant). Crigler-Najjar Type II has residual UGT1A1 activity (responds to phenobarbital, which induces enzyme expression).